Analysts have raised their price target for MedinCell from $31.16 to $35.16. This change reflects increased confidence in the company’s future profitability and outlook, even though there is a slightly higher discount rate and moderated revenue growth projections.
What's in the News
- The U.S. FDA has approved UZEDY as a once-monthly extended-release injectable for maintenance treatment of bipolar I disorder in adults. This product uses MedinCell's proprietary SteadyTeq technology. (Key Developments)
- MedinCell and Teva plan to submit a New Drug Application for Olanzapine LAI, an investigational long-acting injection to treat schizophrenia, in the U.S. during Q4 2025. (Key Developments)
- UZEDY, a long-acting injectable risperidone for schizophrenia, received regulatory approval in South Korea and achieved $117 million in net sales in 2024. MedinCell is eligible for milestone payments and royalties. (Key Developments)
Valuation Changes
- Fair Value Estimate has increased from €31.16 to €35.16, reflecting improved expectations for the company's future performance.
- Discount Rate has risen slightly from 5.98% to 6.18%, indicating a marginally higher perceived risk in future cash flows.
- Revenue Growth projections have decreased from 85.13% to 74.30%, showing more moderated growth expectations.
- Net Profit Margin forecast has improved, increasing from 51.07% to 58.71%.
- Future P/E ratio has risen from 16.51x to 19.53x, suggesting higher valuation multiples anticipated for future earnings.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.